deutetrabenazine Austedo
Selected indexed studies
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (Lancet Psychiatry, 2017) [PMID:28668671]
- Treatment Recommendations for Tardive Dyskinesia. (Can J Psychiatry, 2019) [PMID:30791698]
- Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. (Ann Pharmacother, 2019) [PMID:30136594]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (2017) pubmed
- Deutetrabenazine Therapy and CYP2D6 Genotype. (2012) pubmed
- Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. (2024) pubmed
- Treatment Recommendations for Tardive Dyskinesia. (2019) pubmed
- Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. (2019) pubmed
- Tics and Tourette Syndrome. (2019) pubmed
- Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. (2016) pubmed
- Recent developments in drug-induced movement disorders: a mixed picture. (2019) pubmed
- NKX2-1-Related Disorders. (1993) pubmed
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. (2017) pubmed